Evidence map›Paper›PMID 42243277›Full record

ReviewNature cancer2026

Bacterial engineering for cancer therapy.

Noah Chen, Zaofeng Yang, Nicholas Arpaia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Noah ChenDepartment of Microbiology and Immunology, Columbia University, New York, NY, USA.
Zaofeng YangDepartment of Microbiology and Immunology, Columbia University, New York, NY, USA.
Nicholas ArpaiaDepartment of Microbiology and Immunology, Columbia University, New York, NY, USA. na2697@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-0657-0528

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most critical challenges in cancer therapy is the effective and specific targeting of tumors. The specific accumulation of bacteria within tumor tissue has been exploited for the delivery of therapeutic payloads, including cytotoxic agents and cancer immunotherapeutics, to the tumor site; however, such bacteria-based cancer therapies face challenges related to insufficient colonization and limited efficacy in the clinic. In this Perspective, we discuss mechanisms of bacterial tumor colonization and methods to enhance them, the antitumor mechanisms of bacteria, and considerations for payload selection and delivery.

Indexed as

BacteriaNeoplasmsAnimalsAntineoplastic AgentsDrug Delivery SystemsHumansAntineoplastic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.